The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders

The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.

Compositions and methods for detecting food-based allergens on a surface are disclosed. A composition can include ninhydrin and a protease enzyme. The protease enzyme can be a cysteine protease enzyme, an aspartic protease enzyme, or combinations thereof. In some embodiments, the composition can include a carrier. Methods of detecting a food-based allergen on a surface can include providing a composition including ninhydrin and providing a protease enzyme. The method can include applying the composition and the protease enzyme to the surface. The method can also include allowing the ninhydrin and the protease enzyme to interact with particulates from the surface for a detection period. Detecting the food-based allergen can occur when the composition changes color after the detection period.

Neutrophils contribute to demyelinating autoimmune diseases, yet their phenotype and functions have been elusive to date. The present application shows that ICAM1 surface expression distinguishes extra- from intravascular neutrophils. Transcriptomic analysis of these two subpopulations indicated that neutrophils, once extravasated, acquire macrophage-like properties, including the potential for immunostimulation and MHC class II-mediated antigen presentation. Further, the present application shows that aspartic retroviral-like protease ASPRV1 is specifically expressed by neutrophils in the mouse and human immune system, and correlates with CNS neutrophil infiltration in EAE, multiple sclerosis and neuromyelitis optica.

The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.

A diagnostically useful carrier can include a means for capturing Neurogranin, a means for capturing BACE1 and preferably a means for capturing one or more additional biomarkers. The diagnostically useful carrier can be part of a kit. The kit or the carrier can be used in contacting a sample from a subject with a means for capturing Neurogranin, isolating the means for capturing Neurogranin from the sample, contacting a sample from a subject with a means for capturing BACE1, and isolating the means for capturing BACE1 from the sample. The diagnosis aims to distinguish a neurodegenerative disease, preferably mild Alzheimer's disease, and depression with or without cognitive impairment.

The invention relates to nucleic acid-based sensors and their use in determining enzyme activity, disease detection, and monitoring the effectiveness of enzyme inhibitors.

The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates one or more biomarkers, such as inhibits one or more biomarkers listed in Table 1 and/or increases one or more biomarkers listed in Table 4, in combination with an immunotherapy.